| Active Market | Forge Price1 | Last Funding Round | Trade Eligibility | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Company | Sector & Subsector | Market Activity4   |
Highest Bid | Lowest Ask | Last Matched | +/- to LFR | $ Total Bids |
$ Total Asks |
# Bids |
# Asks |
Current Price |
6-month |
1-year |
Total Funding |
Round | Date | Amount Raised |
Post-Money Valuation3 |
Price |
Key Investors | Common | Preferred | Fund | ||
 | Gelesis | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $207.14M | Series Growth 3 | 7/19/2020 | $100.49M | $801M | $17.27 | Vitruvian Partners, Hambro Perks | ||||
 | Mindstrong Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $160.35M | Series C | 5/21/2020 | $100M | $703.91M | $8.01 | General Catalyst, ARCH Venture Partners, Foresite Capital, 8VC, Optum Ventures, What If Ventures | ||||
 | Omniome | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $153.29M | Series C | 1/9/2020 | $60M | $511M | $4.17 | Madrone Capital Partners, ARCH Venture Partners, Decheng Capital, Domain Associates, Biomatics Capital Partners, Altitude Life Science Ventures, Nan Fung Life Sciences | ||||
 | Orbital Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $373M | Series A | 4/26/2023 | $270M | $705.88M | $1.50 | ARCH Venture Partners, Andreessen Horowitz, Newpath Partners, Abu Dhabi Growth Fund, Redmile Group, Exor N.V., Invus, Moore Strategic Ventures, iGlobe Platinum Fund Group, Casdin Capital, Agent Capital, Alexandria Venture Investments, Rellim Capital Management, Heritage Medical Systems | ||||
 | RayzeBio | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $795.51M | Series D | 9/13/2022 | $159.75M | $599.64M | $2.50 | Viking Global Investors, Sofinnova Investments, Wellington Management, Ally Bridge Group, Sands Capital, Laurion Capital Management, Soleus Capital | ||||
 | UpStream | Healthcare Healthcare Software | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $185M | Series B | 10/6/2022 | $120M | $781.85M | $2.71 | Coatue, Dragoneer Investment Group, Avidity Partners, Define Ventures, Mubadala | ||||
 | Iora Health | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $400.14M | Series F | 2/10/2020 | $150M | $790.13M | $9.49 | Premji Invest, Cox Enterprises, Temasek, Devonshire Investors, .406 Ventures, Flare Capital Partners, Polaris Partners, Khosla Venture | ||||
 | Mercator MedSystems | Healthcare Medical Devices | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $68.55M | Series 1 | 3/4/2021 | $58.37M | $694.21M | $20.00 | Undisclosed Investors | ||||
 | Quartet Health | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $279.11M | Series B | 12/10/2021 | $60M | $646.74M | $11.26 | Independence, GV, Oak HC/FT | ||||
 | Sonoma Biotherapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $365.1M | Series B-1 | 3/28/2023 | $147.78M | $732.39M | $2.96 | Ally Bridge Group, ArrowMark, Avidity Partners, Casdin Capital, Deep Track Capital, Fidelity Management, Frazier Healthcare Partners, GV, Janus Henderson Investors, Mirae Asset, NS Investment, Osage University Partners, Piper Heartland Healthcare Capital, Vertex Ventures HC, 8VC, ARCH Venture Partners, Alexandria Venture Investments, JDRF T1D Fund, LifeForce Capital, Lilly Asia Ventures Biosciences, Octagon Capital, Regeneron | ||||
 | Pathway Genomics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $127.23M | Series E-1 | 1/5/2016 | $40M | $932.69M | $9.50 | International Business Machines | ||||
 | Strata Oncology | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $128.35M | Series A-3 | 7/28/2021 | $84.92M | $561.3M | $34.88 | Wellington Management, Cormorant Asset Management, Monashee Investment Management, Highside Capital Management, Pfizer Ventures, Merck Global Health Innovation Fund, Arboretum Ventures, Deerfield Management, Baird Capital, Renaissance Venture Capital | ||||
 | Truepill | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $929.28M | Series E-1 | 8/16/2023 | $7.49M | $541.17M | $22.68 | Undisclosed Investors | ||||
 | Abpro | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $69.53M | Series F | 3/30/2022 | $2M | $628.78M | $18.00 | Undisclosed Investors | ||||
 | Aetion | Healthcare Healthcare Providers & Services | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $411.43M | Series C | 5/11/2021 | $110M | $585.67M | $13.13 | Warburg Pincus, B Capital, Foresite Capital, New Enterprise Associates, Flare Capital Partners | ||||
 | Welltok | Healthcare Digital Health | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $516.04M | Series E-4NV | 10/16/2020 | $28M | $981.31M | $11.44 | TriZetto, Sillicon Valley Bank, Grupo SURA | ||||
 | Dyno Therapeutics | Healthcare Biotech & Pharma | Limited | $xx.xx | $xx.xx | $xx.xx | xx% | -- | -- | -- | -- | Not available | -- | -- | $111M | Series A | 5/6/2021 | $100M | $539.27M | $44.66 | Andreessen Horowitz, Casdin Capital, GV, Obvious Ventures, Lux Capital | ||||